Creating the Next Generation of Targeted Cancer Therapies

We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugate™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects.

About Cellectar

A Multi-Asset Product Portfolio of Chemotherapeutics

We employ a drug discovery and development approach that allows us to efficiently design, research and advance drug candidates as quickly and safely as possible. In just a couple of years, we have successfully advanced our lead PDC, CLR 131 into a Pivotal Trial for Waldenstrom’s macroglobulinemia as well as other Phase 1 and 2 clinical studies evaluating over ten disease indications. Additionally, we have initiated many collaborations and at least two proprietary programs that are rapidly progressing toward clinical studies.

Explore Our Pipeline

Advancing Innovation in Targeted Therapies

With the challenges that have faced other targeted therapeutic approaches, we have focused on developing the next generation of targeted therapies leveraging our PLE platform technology. We combine knowledge of targeting specificity, uptake and intracellular trafficking, and novel linker chemistry and release mechanisms to allow both a greater diversity in warhead delivery and potentially greater efficacy.

View Our Technology

CureTalks: Next Generation Targeted Cancer Therapies – The Cellectar Story

Learn more about our small biopharmaceutical company and our contribution to the orphan disease armamentarium

Stock Information

IR Contact Information

Company Information

Cellectar Biosciences, Inc.
100 Campus Drive, Suite 207
Florham Park, NJ 07932
T: 608-441-8120
F: 608-441-8121

Investor Relations

LifeSci Advisors
Monique Kosse
Managing Director
T: 212-915-3820

Social Media

Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.